# SCLX catalysts: Scilex Holding Co PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sclx/catalysts

> Scilex Holding Co (SCLX) has no upcoming catalysts in this calendar. The latest recorded is the SEMDEXA (SP-102) trial start, Sep 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Scilex Holding Co |
| Ticker | SCLX (Nasdaq) |
| SEC CIK | 1820190 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/sclx |

## Cash runway

Cash $566K as of 2026-06-30; quarterly burn $6.7M; about 0.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-352464).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 10, 2016 | [Ztlido (lidocaine) complete response letter (CRL)](https://sec-api.dev/pdufa/lidocaine) | SCLX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22207962_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| 2024 | [GLOPERBA (gloperba) trial start](https://sec-api.dev/pdufa/gloperba) | SCLX |  | scheduled | "Forward-looking statements include statements regarding Scilexs declaration and payment of the Dividend and timing thereof (including that the Board may change the Record Date and, as a result, the Payment Date), Scilexs proposed joint venture with IPMC Company and the potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease, Scilexs plans to launch GLOPERBA® in 2024 and plans to initiate Phase 2 trial in 2024 for SP-104." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1820190/000119312524286244/d855930dex991.htm)) |
| Sep 2025 | [SEMDEXA (SP-102) trial start](https://sec-api.dev/pdufa/sp-102) | SCLX |  | completed | "We have extensive clinical and pre-clinical data (including those from multiple Phase 2 clinical trials) with the novel viscous gel formulation of SP-102, and we initiated the second Phase 3 study in September 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm)) |

## Drugs

- [GLOPERBA (gloperba)](https://sec-api.dev/pdufa/gloperba): 
- [Ztlido (lidocaine)](https://sec-api.dev/pdufa/lidocaine): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sclx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SCLX catalysts: Scilex Holding Co PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sclx/catalysts

```bibtex
@misc{secapidev_companies_sclx_catalysts_20261116,
  title        = {SCLX catalysts: Scilex Holding Co PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sclx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sclx_catalysts_20261116","title":"SCLX catalysts: Scilex Holding Co PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sclx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
